- Home
- ROIV vs CIEN Comparison
ROIV vs CIEN Comparison
Compare ROIV & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CIEN
- Stock Information
- Founded
- ROIV 2014
- CIEN 1992
- Country
- ROIV United Kingdom
- CIEN United States
- Employees
- ROIV N/A
- CIEN N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CIEN Telecommunications Equipment
- Sector
- ROIV Health Care
- CIEN Utilities
- Exchange
- ROIV Nasdaq
- CIEN Nasdaq
- Market Cap
- ROIV 7.8B
- CIEN 10.2B
- IPO Year
- ROIV N/A
- CIEN 1997
- Fundamental
- Price
- ROIV $11.40
- CIEN $77.91
- Analyst Decision
- ROIV Buy
- CIEN Buy
- Analyst Count
- ROIV 4
- CIEN 14
- Target Price
- ROIV $17.50
- CIEN $82.62
- AVG Volume (30 Days)
- ROIV 7.9M
- CIEN 2.1M
- Earning Date
- ROIV 08-07-2025
- CIEN 09-03-2025
- Dividend Yield
- ROIV N/A
- CIEN N/A
- EPS Growth
- ROIV N/A
- CIEN N/A
- EPS
- ROIV N/A
- CIEN 0.73
- Revenue
- ROIV $29,053,000.00
- CIEN $4,264,558,000.00
- Revenue This Year
- ROIV $3.28
- CIEN $16.34
- Revenue Next Year
- ROIV $156.84
- CIEN $9.74
- P/E Ratio
- ROIV N/A
- CIEN $106.51
- Revenue Growth
- ROIV N/A
- CIEN 2.86
- 52 Week Low
- ROIV $8.73
- CIEN $44.89
- 52 Week High
- ROIV $13.06
- CIEN $101.44
- Technical
- Relative Strength Index (RSI)
- ROIV 54.55
- CIEN 48.91
- Support Level
- ROIV $10.71
- CIEN $77.11
- Resistance Level
- ROIV $11.58
- CIEN $81.84
- Average True Range (ATR)
- ROIV 0.29
- CIEN 2.17
- MACD
- ROIV 0.00
- CIEN -0.21
- Stochastic Oscillator
- ROIV 62.16
- CIEN 41.83
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CIEN Ciena Corporation
Ciena is a telecommunications equipment provider focused on optical transport technologies, with clients in a number of industries such as communication services providers, web-scale providers, cable operators, government, and large enterprises worldwide. The company provides equipment, software, and services that support transport, switching, aggregation, service delivery, and data traffic management.